title: Pyoderma gangrenosum with the use of sunitinib.
authors.forename: Lincoln D
authors.initials: LD
authors.lastname: Nadauld
authors.forename: Martin B
authors.initials: MB
authors.lastname: Miller
authors.forename: Sandy
authors.initials: S
authors.lastname: Srinivas
mesh_terms: D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001706:Biopsy; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009392:Nephrectomy; D011241:Prednisone / Q000008:administration & dosage; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D017511:Pyoderma Gangrenosum / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D011758:Pyrroles / Q000009:adverse effects*; D012867:Skin / Q000187:drug effects* / Q000473:pathology; D000077210:Sunitinib; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D007211:Indoles; D047428:Protein Kinase Inhibitors; D011758:Pyrroles; D000077210:Sunitinib; D011241:Prednisone